EMA Probes Link With Diabetes Drug Canagliflozin, Toe AmputationEMA Probes Link With Diabetes Drug Canagliflozin, Toe Amputation
The European Medicines Agency is reviewing the type 2 diabetes drug canagliflozin, an SGLT2 inhibitor, after an increase in toe amputations was observed in the ongoing CANVAS trial. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | European Medicines Agency (EMA) | Invokana | SGLT2 Inhibitors